Alliance Medical / IBA Molecular

The CMA investigated the above acquisition involving producers of radiopharmaceutical tracers.

From:
Competition and Markets Authority
Published
15 August 2014
Case type:
Mergers
Case state:
Closed
Market sector:
Healthcare and medical equipment
Outcome:
Mergers - phase 2 clearance
Opened:
1 April 2014
Closed:
15 August 2014

Administrative timetable

  • Published on 10 April 2014 and then updated on 10 July 2014, as required by Rule 7 of the Competition & Markets Authority Rules of Procedure for Merger, Market and Special Reference Groups. Any revisions made to the timetable will be published on this website.
Phase 2 Action
7 September 2014 Statutory deadline
Late August/early September 2014 Publish final report
1 August 2014 Final deadline for all parties’ responses/submissions
July/August 2014 Response hearing(s) (if required)
10 July 2014 Notified provisional findings
Late June 2014 Deadline for all parties’ responses/submissions required before provisional findings
June 2014 Main party hearing, verify information, consider provisional findings
28 April 2014 Publish statement of issues
April 2014 Gather information, issue questionnaires, hear third parties
24 March 2014 Merger reference made

Phase 2

Date of referral: 24.03.14 Statutory deadline: 07.09.14

Contact

Email: [email protected]

Final report published

On 15 August 2014, the CMA published its final report into the completed acquisition by Alliance Medical Limited of the assets of IBA Molecular UK Limited. The CMA cleared the completed acquisition for the reasons set out in the report below:

Responses to provisional findings

Provisional findings

On 10 July the CMA published its provisional findings. Parties wishing to comment should do so by 1 August 2014.

Undertakings

Evidence

Evidence provided to the CMA’s phase 2 inquiry.

Summaries of hearings held with third parties

Responses to issues statement

Initial Submissions

Initial submissions of evidence provided to the CMA’s phase 2 inquiry.

Third parties

Main parties

Issues statement

In this statement, we set out the main issues we are likely to consider in reaching our decisions. This does not preclude the consideration of any other issues which may be identified during the course of our investigation.

Competition Commission news Releases

CC to investigate tracer merger (24.03.14)

Core documents

Phase 1

Decision

Referred

The full text of the decision is available below:

Informal Submission

Completed acquisition by Alliance Medical Molecular Imaging Limited of the assets of IBA Molecular UK Limited - issued 28 January 2014

The Office of Fair Trading is considering whether arrangements are in progress or in contemplation which, if carried into effect, will result in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation may be expected to result in a substantial lessening of competition within any market or markets in the United Kingdom.

Affected sector: Healthcare

Invitation to comment - by 5 February 2014

Please send written representations about any competition or public interest issues to:

Raul Nieto

Victoria House
37 Southampton Row
London
WC1B 4AD

Email: [email protected]
Tel: 020 7211 6866
 
to arrive by 5 February 2014.

Updates to this page

Published 15 August 2014
Contents

Related content